Clinical Trial Update: AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial of AMG 479 in advanced carcinoid tumors and pancreatic neuroendocrine tumors has completed, with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor
• Neuroendocrine Tumor
• Pancreatic Neuroendocrine Tumor

Drugs mentioned

• AMG 479

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Neuroendocrine Tumor, Carcinoid Tumor | Phase 2 | Status: COMPLETED | Results posted: 2017-12-27